
Opinion|Videos|February 28, 2025
Looking Ahead: Strategic Planning for Biosimilar Integration
A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are you preparing for the increasing number of biosimilars entering the market?
- What changes to your biosimilar strategy do you anticipate making in the next 1 to 2 years?
- How do you see the role of biosimilars evolving at your institution and on a broader scale?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5





















